Also listed on Botulinum Toxin Research Associates, Inc., an earlier holder on the record. The recorded assignments below show how it moved.
Collateral for a security interest recorded Feb 7, 2025 (Hayfin Services LLP).
Term ends Jan 3, 2027 · High confidence
20-year base term ended Dec 22, 2023
Held by Revance Therapeutics, Inc.
Filed Mar 3, 2008 as application 12/073,245 · Granted Aug 14, 2012
Base term plus 1108 days of patent term adjustment (USPTO delay)
Today
2003
2027
Clock starts
Dec 22, 2003
Dec 22, 2003
Term ends
Jan 3, 2027
Jan 3, 2027
Granted
Aug 14, 2012
Aug 14, 2012
base term
patent term adjustment
fee events
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
1,108
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
None
Terminal disclaimer
No disclaimer on this record.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
8
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term runs 1108 days past its 20-year base term on prosecution delay. All three maintenance fees are recorded paid; no more fees are due. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Dec 22, 2003, when application 10/740,755, the earliest non-provisional in its chain, was filed (this one was filed Mar 3, 2008) | Dec 22, 2023 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +1108 days, USPTO patent term adjustment record | Jan 3, 2027 | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jan 3, 2027 | High confidence |
This family
| US 7,459,164 | Term ended Jul 2025 | Jul 2025 |
| US 7,491,403 | Term ended no later than Dec 2023 | no later than Dec 2023 |
| US 7,691,394 | Term ended May 2023 | May 2023 |
| Application PCT/US2006/015459 | PCT application no patent term | no patent term |
| US 8,580,745 | Lapsed on the fee record Nov 2025 | Nov 2025 |
| US 8,241,640 | this patent Jan 2027 | Jan 2027 |
| US 8,679,486 | Term ended May 2023 | May 2023 |
| Application 14/225,011 | Abandoned not computed | not computed |
Every application listed has its file history here. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jun 17, 2008 Reel 21105, frame 406 | Borodic, Gary E. | Botulinum Toxin Research Associates, Inc. | Assignment of Assignor's Interest |
| Jun 3, 2016 Reel 38870, frame 160 | Botulinum Toxin Research Associates, Inc. | Revance Therapeutics, Inc. | Assignment of Assignor's Interest |
| Mar 18, 2022 Reel 59437, frame 654 | Revance Therapeutics, Inc. | Athyrium Buffalo LP | Security Interest |
| Feb 7, 2025 Reel 70153, frame 630 | Athyrium Buffalo LP | Revance Therapeutics, Inc. | Release of Security Interest |
| Feb 7, 2025 Reel 70153, frame 663 | Revance Therapeutics, Inc.; Crown Laboratories, Inc. | Hayfin Services LLP, as Administrative Agent | Security Interest |
| Feb 7, 2025 Reel 70153, frame 736 | Revance Therapeutics, Inc.; Bellus Medical, LLC; Crown Laboratories, Inc. | Hayfin Services LLP, as Administrative Agent | Security Interest |
| Feb 17, 2025 Reel 70239, frame 739 | Revance Therapeutics, Inc. | Jpmorgan Chase Bank, N.a. | Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Jan 2027
Term ends Jan 3, 2027. No further fees fall due before then
Note
The 1108 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Citations
14
later US patents cite this one
That is above the median of utility patents granted in 2012 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.